Amgen faces US whistleblower suit related to Enbrel and Aranesp
This article was originally published in Scrip
Executive Summary
Amgen is facing a lawsuit by an unidentified whistleblower, who accuses the company of illegally marketing Enbrel (etanercept) and Aranesp (darbepoetin alfa) in the US in order to generate more profit from the blockbuster products.